<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00427037</url>
  </required_header>
  <id_info>
    <org_study_id>Vitamin D-2006</org_study_id>
    <nct_id>NCT00427037</nct_id>
  </id_info>
  <brief_title>Cholecalciferol (Vitamin D3) Therapy in Chronic Kidney Disease (CKD) Subjects</brief_title>
  <official_title>Efficacy of Cholecalciferol (Vitamin D3) Therapy in Correcting Vitamin D Insufficiency and Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease: A Randomized, Placebo Controlled Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atlanta VA Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Atlanta VA Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 12 week pilot and feasibility study with an enrollment goal of 30 subjects. Half of
      the subjects will be randomized to vitamin D3 and the other half will receive a placebo.
      Subjects will be referred from the nutrition or renal clinic at Emory. CKD stage 3 and 4
      patients will be eligible for participation if they have been determined to have vitamin D
      deficiency and are not on treatment with vitamin D or vitamin D analogues. Subjects will sign
      an informed consent form after reviewing the protocol in detail with the principal
      investigator. A questionnaire would collect information about dietary vitamin D intake,
      sunlight exposure, and any symptoms of vitamin D deficiency. The subject will have baseline
      levels of serum vitamin D (25-hydroxyvitamin D), parathyroid hormone (PTH), serum calcium and
      phosphate, creatinine and other markers of bone turnover. The questionnaires and the blood
      draws would be repeated on the 6th and 12th week of the study. Subjects will be given 12
      pills of each containing either 50,000 IU vitamin D or placebo and asked to take one pill a
      week. They would be scheduled to return to the clinic after 6 weeks and blood measurements
      would be repeated. Subjects will be asked to revisit for their final visit at the 12th week
      when they would have their last blood draw and assessment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vitamin D supplementation in reducing secondary hyperparathyroidism in chronic kidney disease
      patients, stage 3 and 4: A randomized, placebo controlled pilot study Problem of interest
      Chronic Kidney Disease (CKD) patients suffer from severe metabolic bone disease, which
      represents a formidable challenge to physicians. Defective vitamin D metabolism, and
      secondary parathyroid activation have been suggested as possible causes. Vitamin D is
      important for musculoskeletal health. Vitamin D can be obtained from the diet or made in the
      skin from exposure to sunlight, but it has to be converted by the kidneys into calcitriol,
      the active form in order to be effective. Decreased kidney mass in CKD patients causes
      reduced capability to convert vitamin D into calcitriol due to less 1-alpha hydroxylase
      enzyme levels. Current standard of care for patients with chronic renal disease is treatment
      with vitamin D analogues such as Rocaltrol or Hectoral. However, these medications have the
      potential to cause hypercalcemia. Studies have shown that calcitriol production becoming
      dependent on 25- hydroxyvitamin D availability in moderate CKD patients. There is speculation
      that there is still some &quot;reserve&quot; left for the generation of calcitriol from vitamin D in
      these patients.

      The main question being posed in this study is:

      Primary: Can a weekly high dose supplementation of cholecalciferol be effective in raising
      25(OH)D levels in patients with CKD and can this reduce parathyroid hormone levels in
      pre-dialysis chronic kidney disease patients?

      Study Design This is an 12 week pilot and feasibility study with an enrollment goal of 30
      subjects. Half of the subjects will be randomized to vitamin D3 and the other half will
      receive a placebo. Subjects will be referred from the nutrition or renal clinic at Emory. CKD
      stage 3 and 4 patients will be eligible for participation if they have been determined to
      have vitamin D deficiency and are not on treatment with vitamin D or vitamin D analogues.
      Subjects will sign an informed consent form after reviewing the protocol in detail with the
      principal investigator. A questionnaire would collect information about dietary vitamin D
      intake, sunlight exposure, and any symptoms of vitamin D deficiency. The subject will have
      baseline levels of serum vitamin D (25-hydroxyvitamin D), parathyroid hormone (PTH), serum
      calcium and phosphate, creatinine and other markers of bone turnover. The questionnaires and
      the blood draws would be repeated on the 6th and 12th week of the study. Subjects will be
      given 12 pills of each containing either 50,000 IU vitamin D3 or placebo and asked to take
      one pill a week. They would be scheduled to return to the clinic after 6 weeks and blood
      measurements would be repeated. Subjects will be asked to revisit for their final visit at
      the 12th week when they would have their last blood draw and assessment.

      Treatment This is a randomized control trial. Only half of the subjects will receive vitamin
      D treatment and the other half placebo. If at the end of the study, the subject is still
      vitamin D deficiency, they will be referred to an endocrinologist or to their primary doctor
      for treatment.

      Scientific advancement If successful, this study would provide the necessary preliminary data
      in order to conduct a larger randomized controlled study supplementing vitamin D in chronic
      kidney disease patients. One potential area of study would be to see whether subjects
      supplemented with vitamin D were able to raise their active vitamin D levels using the
      &quot;reserve&quot; hydroxylase enzyme in the kidneys compared to those subjects who were just
      supplemented with a placebo. This study is necessary in order to determine whether weekly
      intake of a high dose vitamin D is sufficient to decrease the parathyroid hormone levels in
      the given time frame.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>25-hydroxyvitamin D</measure>
    <time_frame>3 months</time_frame>
    <description>25-hydroxyvitamin D measured in serum by ELISA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bone Turnover Marker-CTX</measure>
    <time_frame>12 weeks</time_frame>
    <description>Blood levels of C-telopeptide</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cholecalciferol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>D3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <description>50,000 IU weekly by mouth</description>
    <arm_group_label>Cholecalciferol</arm_group_label>
    <other_name>Vitamin D3 is cholecalciferol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>identical placebo pill orally by mouth</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>D3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-85

          -  CKD stage 3-4 (GFR 15-59 ml/min/1.73 m2 body surface area, calculated by using the
             MDRD Study equation GFR Calculator)

          -  serum 25(OH)D concentrations â‰¤ 30 ng/mL, and serum PTH levels &gt;70 pg/mL documented
             within the last six months

        Exclusion Criteria:

          -  History of liver failure (serum AST or ALT &gt; 3-fold the upper limit of normal)

          -  requiring dialysis at any stage of the study

          -  history of intestinal malabsorption or chronic diarrhea

          -  serum calcium level (corrected for serum albumin) &gt; 10.5 mg/dL

          -  calcium x phosphorus product &gt;70

          -  treatment with more than 1000 IU of vitamin D per day, or current treatment with a
             vitamin D analogue or calcimimetic

          -  an anti-epileptic medication and other medications which can affect vitamin D
             metabolism (e.g., phenobarbital, phenytoin, rifampicin)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vin Tangpricha, M.D. Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory Clinic</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.medscape.com/viewarticle/572253_1</url>
    <description>Medscape Link</description>
  </link>
  <results_reference>
    <citation>Chandra P, Binongo JN, Ziegler TR, Schlanger LE, Wang W, Someren JT, Tangpricha V. Cholecalciferol (vitamin D3) therapy and vitamin D insufficiency in patients with chronic kidney disease: a randomized controlled pilot study. Endocr Pract. 2008 Jan-Feb;14(1):10-7.</citation>
    <PMID>18238736</PMID>
  </results_reference>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2007</study_first_submitted>
  <study_first_submitted_qc>January 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2007</study_first_posted>
  <results_first_submitted>January 14, 2009</results_first_submitted>
  <results_first_submitted_qc>February 11, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 12, 2009</results_first_posted>
  <last_update_submitted>July 20, 2015</last_update_submitted>
  <last_update_submitted_qc>July 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Atlanta VA Medical Center</investigator_affiliation>
    <investigator_full_name>Vin Tangpricha</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Vitamin D deficiency</keyword>
  <keyword>Chronic Kidney Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study subjects were recruited from Nephrology and Endocrinology clinics at Emory University School of Medicine</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>This is a matching placebo</description>
        </group>
        <group group_id="P2">
          <title>Cholecalciferol</title>
          <description>This is vitamin D3 or Cholecalciferol</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>This is a matching placebo</description>
        </group>
        <group group_id="B2">
          <title>Cholecalciferol</title>
          <description>This is vitamin D3 or Cholecalciferol</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.5" spread="10.4"/>
                    <measurement group_id="B2" value="62.2" spread="11"/>
                    <measurement group_id="B3" value="60.8" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Bone Turnover Marker-CTX</title>
        <description>Blood levels of C-telopeptide</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo
Placebo: identical placebo pill orally by mouth</description>
          </group>
          <group group_id="O2">
            <title>Cholecalciferol</title>
            <description>D3
Cholecalciferol: 50,000 IU weekly by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Turnover Marker-CTX</title>
          <description>Blood levels of C-telopeptide</description>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" lower_limit="0.14" upper_limit="0.4"/>
                    <measurement group_id="O2" value="0.29" lower_limit="0.18" upper_limit="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>25-hydroxyvitamin D</title>
        <description>25-hydroxyvitamin D measured in serum by ELISA</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>This is a matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Cholecalciferol</title>
            <description>This is vitamin D3 or Cholecalciferol</description>
          </group>
        </group_list>
        <measure>
          <title>25-hydroxyvitamin D</title>
          <description>25-hydroxyvitamin D measured in serum by ELISA</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6" lower_limit="12.8" upper_limit="27.1"/>
                    <measurement group_id="O2" value="17.3" lower_limit="11.8" upper_limit="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.5" lower_limit="13.4" upper_limit="28.4"/>
                    <measurement group_id="O2" value="49.4" lower_limit="33.9" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 Months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>This is a matching placebo</description>
        </group>
        <group group_id="E2">
          <title>Cholecalciferol</title>
          <description>This is vitamin D3 or Cholecalciferol</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vin Tangpricha</name_or_title>
      <organization>Emory University School of Medicine</organization>
      <phone>404-727-7254</phone>
      <email>vin.tangpricha@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

